Investigator Initiated Trial: Chronic lymphocytic leukemia (CLL) or Large Cell Lymphoma
Lilly Oncology is dedicated to delivering innovative treatment approaches with the goal of improving the outcomes of people living with cancer. We are driven to accelerate the pace and progress of cancer care by developing a broad portfolio of therapies, including those tailored to unique patients and those that modulate the immune system. Lilly’s commitment to improving the length and quality of people’s lives is achieved through its internal drug development programs and its support of Investigator Initiated Research
In Scope:
- CLL (truly novel concepts if not duplicative of current approved concepts).
- MCL (only if truly novel and non-duplicative concepts
- Large Cell Lymphoma
- Translational research related to pirtobrutinib and CLL
- Other B cell malignancies with an unmet medical need, provided reasonable scientific rationale exists to suggest targeting the BTK pathway could lead to improvement in outcomes, may be considered
Out of Scope:
- Proposals which directly overlap with registration development program
- Proposals duplicative of currently approved concepts or concepts under consideration
- Proposals with no strong pre-clinical rationale
- Non-hematology indications
- MZL
- GVHD
- ITP
- Post-Transplant Lymphoproliferative Disease (PTLD)
- CNSL
- FL
- Richter’s Transformation
PIRA™ suggested Proposal
PIRA™ proposals are AI generated and are not reviewed or endorsed by the sponsoring company.